Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation
Grant
US12589118B2
Kind: B2
Mar 31, 2026
Assignee
EVER NUERO PHARMA GMBH
Inventors
Stefan Winter, Herbert Mössler
Abstract
Disclosed is cerebrolysin for use in reducing mortality in CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) patients.
CPC Classifications
A61K 38/00
A61K 38/1709
A61K 38/185
A61K 38/17
A61K 38/18
C07K 14/47
C07K 14/4705
C07K 14/475
C07K 14/48
A61P 25/28
A61P 25/00
A61P 9/00
A61P 9/10
Filing Date
2018-08-28
Application No.
16642307
Claims
15